Ethypharm SAS
Ethypharm SAS, a prominent player in the pharmaceutical industry, is headquartered in France and operates extensively across Europe and beyond. Founded in 2000, the company has established itself as a leader in the development of innovative medicines, particularly in the fields of pain management and critical care. Ethypharm's core offerings include a range of unique drug delivery systems and specialty pharmaceuticals that address unmet medical needs. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including strategic partnerships and a robust pipeline of products. With a strong market position, Ethypharm continues to make notable contributions to healthcare, enhancing patient outcomes through its specialised therapeutic solutions.
DitchCarbon Score
How does Ethypharm SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ethypharm SAS's score of 31 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ethypharm SAS's reported carbon emissions
Ethypharm SAS, headquartered in France, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions data to analyse. In the absence of concrete emissions statistics, it is important to note that the company has not outlined any specific reduction targets or commitments related to climate action. This lack of publicly available information may suggest that Ethypharm SAS is still in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability and carbon neutrality, Ethypharm SAS may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ethypharm SAS is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
